Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.22B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 2.17M
Average 2.73M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +57.5% | +154.3% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +57.5% over three years. Forward estimates point to Revenue at +154.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Sarepta Therapeutics, Inc. NASDAQ:SRPT | $1.72B | $16.07 | Undervalued | 27.8 | -14.02% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | +3.68% |
REGENXBIO Inc. NASDAQ:RGNX | $505.18M | $7.64 | Not rated | -1.5 | -33.95% |
Neurogene Inc. NASDAQ:NGNE | $378.15M | $23.93 | Not rated | -7.1 | +12.40% |
Benitec Biopharma Inc. NASDAQ:BNTC | $315.40M | $9.04 | Not rated | -12.3 | -38.05% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | $2.30 | Not rated | -1.7 | -25.70% |
Abeona Therapeutics Inc. NASDAQ:ABEO | $138.30M | $2.42 | Not rated | 4.9 | -41.94% |
Voyager Therapeutics, Inc. NASDAQ:VYGR | $107.66M | $1.73 | Not rated | -1.9 | -60.64% |
Continue the stock analysis
Jump to another research area for this company.